Krystal Biotech, Inc. (KRYS) financial statements (2021 and earlier)

Company profile

Business Address 2100 WHARTON STREET
PITTSBURGH, PA 15203
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:27119450
Cash and cash equivalents26818850
Short-term investments36 
Other undisclosed cash, cash equivalents, and short-term investments00 
Prepaid expense  0
Other current assets  0
Other undisclosed current assets42 
Total current assets:27519650
Noncurrent Assets
Operating lease, right-of-use asset33
Property, plant and equipment3180
Long-term investments and receivables 0 
Long-term investments 0 
Other noncurrent assets21 
Total noncurrent assets:36130
TOTAL ASSETS:31120950
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities310
Accounts payable210
Accrued liabilities100
Debt 0 
Other liabilities00 
Other undisclosed current liabilities1320
Total current liabilities:1531
Noncurrent Liabilities
Long-term debt and lease obligation33 
Operating lease, liability33
Other undisclosed noncurrent liabilities(3)  
Total noncurrent liabilities:33 
Total liabilities:1961
Stockholders' equity
Stockholders' equity attributable to parent29220349
Additional paid in capital36324259
Accumulated other comprehensive income00 
Accumulated deficit(71)(39)(9)
Total stockholders' equity:29220349
TOTAL LIABILITIES AND EQUITY:31120950

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2017
Operating expenses(33)(22)(5)
Other undisclosed operating income00 
Operating loss:(33)(22)(5)
Nonoperating expense  (3)
Net loss:(33)(22)(8)
Other undisclosed net income attributable to parent13 
Net loss available to common stockholders, diluted:(32)(19)(8)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2017
Net loss:(33)(22)(8)
Comprehensive loss:(33)(22)(8)
Other undisclosed comprehensive income, net of tax, attributable to parent13 
Comprehensive loss, net of tax, attributable to parent:(32)(19)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: